Catalyst Pharmaceuticals Inc $ 3.60 -0.07 (-1.91%)
Volume:
1,648,843
Avg Vol (1m):
1,861,638
Market Cap $:
373.13 Mil
Enterprise Value $:
246.14 Mil
P/E (TTM):
5.37
P/B:
2.44
Financial Strength | 10/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1105.3 | ||
| Equity-to-Asset | 0.9 | ||
| Interest Coverage | No Debt | ||
| Piotroski F-Score | 8 | ||
| Altman Z-Score | 14.08 | ||
| Beneish M-Score | -0.72 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 34.43 | ||
| Net Margin % | 60.48 | ||
| ROE % | 67.04 | ||
| ROA % | 56.44 | ||
| ROC (Joel Greenblatt) % | 5942.32 |
CPRX
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 5.37 | ||
| Forward PE Ratio | 10.29 | ||
| PE Ratio without NRI | 5.37 | ||
| Price-to-Owner-Earnings | 5.49 | ||
| PB Ratio | 2.44 | ||
| PS Ratio | 3.25 | ||
| Price-to-Free-Cash-Flow | 8.67 | ||
| Price-to-Operating-Cash-Flow | 8.67 | ||
| EV-to-EBIT | 6.05 | ||
| EV-to-EBITDA | 5.91 | ||
| EV-to-Revenue | 2.08 | ||
| Current Ratio | 7.86 | ||
| Quick Ratio | 7.6 | ||
| Days Inventory | 49.98 | ||
| Days Sales Outstanding | 18.14 | ||
| Days Payable | 44.17 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 2.44 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 3.67 | ||
| Price-to-Graham-Number | 0.76 | ||
| Earnings Yield (Greenblatt) % | 16.53 |